Daisuke Kadowaki

Prof. Daisuke Kadowaki

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Kidney International
Verified
Journal Article
Closed access
PDF file
HWHiroshi Watanabe
Hiroshi Watanabe
YMYohei Miyamoto
Yohei Miyamoto
DHDaisuke Honda
Daisuke Honda
HTHisae Tanaka
Hisae Tanaka
QWQiong Wu
Qiong Wu
TMToru Maruyama
Toru Maruyama

8 January 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KNKohei Nagumo
Kohei Nagumo
MTMotohiko Tanaka
Motohiko Tanaka
Victor ChuangVictor Chuang
Victor Chuang
HSHiroko Setoyama
Hiroko Setoyama
HWHiroshi Watanabe
Hiroshi Watanabe
TMToru Maruyama
Toru Maruyama
The degree of oxidized cysteine (Cys) 34 in human serum albumin (HSA), as determined by high performance liquid chromatography (HPLC), is correlated with oxidative stress related pathological conditions. In order to further characterize the oxidation of Cys34-HSA at the molecular level and to develop a suitable analytical method for a rapid and sensitive clinical laboratory analysis, the use of electrospray ionization time-of-flight mass spectrometer (ESI-TOFMS) was evaluated. A marked increase in the cysteinylation of Cys34 occurs in chronic liver and kidney diseases and diabetes mellitus. A significant positive correlation was observed between the Cys-Cys34-HSA fraction of plasma samples obtained from 229 patients, as determined by ESI-TOFMS, and the degree of oxidized Cys34-HSA determined by HPLC. The Cys-Cys34-HSA fraction was significantly increased with the progression of liver cirrhosis, and was reduced by branched chain amino acids (BCAA) treatment. The changes in the Cys-Cys34-HSA fraction were significantly correlated with the alternations of the plasma levels of advanced oxidized protein products, an oxidative stress marker for proteins. The binding ability of endogenous substances (bilirubin and tryptophan) and drugs (warfarin and diazepam) to HSA purified from chronic liver disease patients were significantly suppressed but significantly improved by BCAA supplementation. Interestingly, the changes in this physiological function of HSA in chronic liver disease were correlated with the Cys-Cys34-HSA fraction. In conclusion, ESI-TOFMS is a suitable high throughput method for the rapid and sensitive quantification of Cys-Cys34-HSA in a large number of samples for evaluating oxidative stress related chronic disease progression or in response to a treatment.

7 November 2014 in Pharmacology Research & Perspectives
Verified
Journal Article
Open access
PDF file
HWHiroshi Watanabe
Hiroshi Watanabe
YMYohei Miyamoto
Yohei Miyamoto
YEYuki Enoki
Yuki Enoki
YIYu Ishima
Yu Ishima
DKDaisuke Kadowaki
Daisuke Kadowaki
TMToru Maruyama
Toru Maruyama
The major cause of death in patients with chronic kidney disease (CKD) is cardiovascular disease. Here, p‐Cresyl sulfate (PCS), a uremic toxin, is considered to be a risk factor for cardiovascular disease in CKD. However, our understanding of the vascular toxicity induced by PCS and its mechanism is incomplete. The purpose of this study was to determine whether PCS enhances the production of reactive oxygen species (ROS) in vascular endothelial and smooth muscle cells, resulting in cytotoxicity. PCS exhibited pro‐oxidant properties in human umbilical vein endothelial cells (HUVEC) and aortic smooth muscle cells (HASMC) by enhancing NADPH oxidase expression. PCS also up‐regulates the mRNA levels and the protein secretion of monocyte chemotactic protein‐1 (MCP‐1) in HUVEC. In HASMC, PCS increased the mRNA levels of alkaline phosphatase (ALP), osteopontin (OPN), core‐binding factor alpha 1, and ALP activity. The knockdown of Nox4, a subunit of NADPH oxidase, suppressed the cell toxicity induced by PCS. The vascular damage induced by PCS was largely suppressed in the presence of probenecid, an inhibitor of organic anion transporters (OAT). In PCS‐overloaded 5/6‐nephrectomized rats, plasma MCP‐1 levels, OPN expression, and ALP activity of the aortic arch were increased, accompanied by the induction of Nox4 expression. Collectively, the vascular toxicity of PCS can be attributed to its intracellular accumulation via OAT, which results in an enhanced NADPH oxidase expression and increased ROS production. In conclusion, we found for the first time that PCS could play an important role in the development of cardiovascular disease by inducing vascular toxicity in the CKD condition.

8 February 2011 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
YMYohei Miyamoto
Yohei Miyamoto
HWHiroshi Watanabe
Hiroshi Watanabe
TNTsuyoshi Noguchi
Tsuyoshi Noguchi
SKShunsuke Kotani
Shunsuke Kotani
MNMakoto Nakajima
Makoto Nakajima
TMToru Maruyama
Toru Maruyama
Background.p -Cresyl sulfate (PCS), a recently identified anionic uremic toxin, is the main circulating metabolite of p -cresol. In cases of chronic kidney disease (CKD), it might be associated with cardiovascular outcomes and the progression of CKD. However, the renal excretion pathway of PCS is currently unknown. The objective of the present study was to determine whether organic anion transporters (OATs), which are renal tubular basolateral membrane transporters, play an important role in this process. Methods. The uptake of PCS was investigated using rat renal cortical slices and human proximal tubular cells (HK-2). The active uptake velocity was calculated by subtracting the uptake velocity at 4°C (nonspecific uptake) from that at 37°C. Results. As evidenced by renal cortical slice experiments, the uptake of PCS was saturable with a mean Km of 231.6 μM, indicating that the active transport is involved in the basolateral uptake of PCS. Similar results were also observed in HK-2 cells. The active transport of PCS was significantly suppressed by inhibitors of OATs, such as probenecid, benzylpenicillin, p -aminohippuric acid and estrone sulfate. Similar inhibitions were observed in the presence of indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropionate, OATs substrates among uremic toxins. In contrast, digoxin and tetraethylammonium that did not interact with OATs had little inhibitory effect. Conclusions. The findings of the present study strongly suggest that PCS serves as a substrate for OATs, is preferentially recognized by OAT3 and plays a key role in the renal tubular secretion process.

1 July 2012 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
HWHiroshi Watanabe
Hiroshi Watanabe
TNTsuyoshi Noguchi
Tsuyoshi Noguchi
YMYohei Miyamoto
Yohei Miyamoto
DKDaisuke Kadowaki
Daisuke Kadowaki
SKShunsuke Kotani
Shunsuke Kotani
TMToru Maruyama
Toru Maruyama
Recently, p-cresyl sulfate (PCS) has been identified as a protein-bound uremic toxin. Moreover, the serum-free concentration of PCS, which is associated with its efficacy of hemodialysis, appears to be a good predictor of survival in chronic kidney disease (CKD). We previously found that PCS interacts with indoxyl sulfate (IS), another sulfate-conjugated uremic toxin, during renal excretion via a common transporter. The purpose of this study was to further investigate the interaction between PCS and IS on the binding to human serum albumin (HSA). Here, we used ultrafiltration to show that there is only one high-affinity binding site for PCS, with a binding constant on the order of 105 M−1 (i.e., comparable to that of IS). However, a binding constant of the low-affinity binding site for PCS is 2.5-fold greater than that for IS. Displacement of a fluorescence probe showed that PCS mainly binds to site II, which is the high-affinity site for PCS, on HSA. This finding was further supported by experiments using mutant HSA (R410A/Y411A) that displayed reduced site II ligand binding. A Klotz analysis showed that there could be competitive inhibition between PCS and IS on HSA binding. A similar interaction between PCS and IS on HSA was also observed under the conditions mimicking CKD stage 4 to 5. The present study suggests that competitive interactions between PCS and IS in both HSA binding and the renal excretion process could contribute to fluctuations in their free serum concentrations in patients with CKD.

20 March 2019 in Clinical and Experimental Nephrology
Verified
Journal Article
Open access
PDF file
MSMiyu Sueyoshi
Miyu Sueyoshi
MFMasaki Fukunaga
Masaki Fukunaga
MMMizue Mei
Mizue Mei
ANAtsushi Nakajima
Atsushi Nakajima
GTGaku Tanaka
Gaku Tanaka
DKDaisuke Kadowaki
Daisuke Kadowaki
Background Constipation is frequently observed in patients with chronic kidney disease (CKD). Lactulose is expected to improve the intestinal environment by stimulating bowel movements as a disaccharide laxative and prebiotic. We studied the effect of lactulose on renal function in adenine-induced CKD rats and monitored uremic toxins and gut microbiota. Methods Wistar/ST male rats (10-week-old) were fed 0.75% adenine-containing diet for 3 weeks to induce CKD. Then, they were divided into three groups and fed as follows: control, normal diet; and 3.0- and 7.5-Lac, 3.0% and 7.5% lactulose-containing diets, respectively, for 4 weeks. Normal diet group was fed normal diet for 7 weeks. The rats were observed for parameters including renal function, uremic toxins, and gut microbiota. Results The control group showed significantly higher serum creatinine (sCr) and blood urea nitrogen (BUN) 3 weeks after adenine feeding than at baseline, with a 8.5-fold increase in serum indoxyl sulfate (IS). After switching to 4 weeks of normal diet following adenine feeding, the sCr and BUN in control group remained high with a further increase in serum IS. In addition, tubulointerstitial fibrosis area was increased in control group. On the other hand, 3.0- and 7.5-Lac groups improved sCr and BUN levels, and suppressed tubulointerstitial fibrosis, suggesting preventing of CKD progression by lactulose. Lac groups also lowered level of serum IS and proportions of gut microbiota producing IS precursor. Conclusion Lactulose modifies gut microbiota and ameliorates CKD progression by suppressing uremic toxin production.